Jump to content

Search the Community

Showing results for tags 'castrate resistant'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 3 results

  1. Jim Marshall (not a doctor) said ... If you have castrate-resistant prostate cancer, common treatments that your doctor may add to your regular ADT treatment include: Docetaxel (Taxotere) Enzalutamide (Xtandi) or Abiraterone (Zytiga) Cabazitaxel (Jevtana). But what are your doctor's drug choices when the cancer is no longer under control after all three options? If you responded to docetaxel, your doctor knows you may well respond again to another dosing of docetaxel. But this increases your risk of side effects - especially peripheral neuropathy or nail di
  2. Thanks to Chuck Maack for alerting us to this. A collaboration between leading US and British Cancer Centres has been described as a landmark study. Click on this link to read a report of the study. Chuck's comment This appears to be terrific news. The problem now is whether or not the researchers get fast-track funding to continue their research to determine which medications currently are correct for which genomic defects, and what medications are available and might be used singularly or in combination with other medications to go after the other genomic defects. Then…
  3. The journal UROLOGY has published a number of online presentations by 5 leading medical oncologists and urologists looking at the new options for the treatment of patients with Metastatic Castrate Resistant Prostate Cancer. Whilst all of these presentations are of interest to men with advanced prostate cancer, the 2 roundtable discussions (Clinical Treatment and Patient Treatment) are especially recommended. Click here to view the presentations
×
×
  • Create New...